share_log

Reneo Pharmaceuticals Analyst Ratings

Reneo Pharmaceuticalsアナリストレーティング

Benzinga ·  2023/08/28 06:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/28/2023 380% HC Wainwright & Co. → $30 Initiates Coverage On → Buy
07/03/2023 268% B of A Securities → $23 Initiates Coverage On → Buy
09/19/2022 396% HC Wainwright & Co. → $31 Assumes → Buy
05/18/2022 188% Piper Sandler $45 → $18 Maintains Overweight
03/24/2022 140% SVB Leerink $25 → $15 Maintains Outperform
01/27/2022 348% Baird → $28 Initiates Coverage On → Outperform
12/21/2021 348% HC Wainwright & Co. → $28 Initiates Coverage On → Buy
11/22/2021 620% Ladenburg Thalmann → $45 Initiates Coverage On → Buy
05/04/2021 300% SVB Leerink → $25 Initiates Coverage On → Outperform
05/04/2021 284% Jefferies → $24 Initiates Coverage On → Buy
05/04/2021 620% Piper Sandler → $45 Initiates Coverage On → Overweight

What is the target price for Reneo Pharmaceuticals (RPHM)?

The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on August 28, 2023. The analyst firm set a price target for $30.00 expecting RPHM to rise to within 12 months (a possible 380.00% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?

The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals initiated their buy rating.

When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?

While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a initiated with a price target of $0.00 to $30.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $6.25, which is within the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする